{"id":"NCT02413580","sponsor":"Grifols Therapeutics LLC","briefTitle":"A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations","officialTitle":"A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2018-04","completion":"2018-04","firstPosted":"2015-04-10","resultsPosted":"2020-04-24","lastUpdate":"2020-04-24"},"enrollment":49,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myasthenia Gravis Exacerbations"],"interventions":[{"type":"BIOLOGICAL","name":"IGIV-C","otherNames":[]}],"arms":[{"label":"IGIV-C Treatment","type":"EXPERIMENTAL"}],"summary":"This was a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.","primaryOutcome":{"measure":"Change in Quantitative Myasthenia Gravis (QMG) Scale Score","timeFrame":"From Baseline (Day 0) to Day 14","effectByArm":[{"arm":"IGIV-C Treatment","deltaMin":-6.4,"sd":5.15}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":20},"locations":{"siteCount":31,"countries":["Argentina","Belgium","Canada","Czechia","Estonia","France","Hungary","Latvia","Poland","Romania","Russia","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":49},"commonTop":["Headache","Pyrexia","Urticaria","Influenza like illness","Vomiting"]}}